{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:30:09Z","timestamp":1791948609322,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":160,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100588","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:24:45Z","timestamp":1655213085000},"page":"100588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1437-7357","authenticated-orcid":false,"given":"Yash","family":"Suri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5013-1303","authenticated-orcid":false,"given":"Jonathan Parham","family":"Yasmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-3880","authenticated-orcid":false,"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2022.100588_bib0001","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.mcna.2020.08.007","article-title":"Screening for prostate cancer","volume":"104","author":"Carlsson","year":"2020","journal-title":"Med. Clin. North Am."},{"issue":"24","key":"10.1016\/j.ctarc.2022.100588_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100588_bib0003","first-page":"7","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.ctarc.2022.100588_bib0004","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/cncr.31549","article-title":"Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics","volume":"124","author":"Negoita","year":"2018","journal-title":"Cancer."},{"issue":"19","key":"10.1016\/j.ctarc.2022.100588_bib0005","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Rec-ommendations","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100588_bib0006","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"149","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100588_bib0007","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100588_bib0008","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100588_bib0009","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnic-ity, and geographic location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am. J. Mens. Health"},{"issue":"7","key":"10.1016\/j.ctarc.2022.100588_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2015-202993","article-title":"Young-age prostate cancer","volume":"68","author":"Hussein","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"9360","key":"10.1016\/j.ctarc.2022.100588_bib0011","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","article-title":"Prostate cancer epidemiology","volume":"361","author":"Gr\u00f6nberg","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100588_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J. Urol."},{"issue":"22","key":"10.1016\/j.ctarc.2022.100588_bib0013","doi-asserted-by":"crossref","DOI":"10.7314\/APJCP.2014.15.22.9575","article-title":"Epidemiology, etiology, diagnosis and treatment of pros-tate cancer","volume":"15","author":"Daniyal","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100588_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/pros.23923","article-title":"Disparities in prostate cancer incidence and mortality rates: solvable or not?","volume":"80","author":"Badal","year":"2020","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100588_bib0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1210\/me.2013-1039","article-title":"The molecular and genomic basis for prostate cancer health disparities","volume":"27","author":"Minireview","year":"2013","journal-title":"Mol. Endo-crinol."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100588_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s11934-017-0724-5","article-title":"African-American prostate cancer disparities","volume":"18","author":"Smith","year":"2017","journal-title":"Curr. Urol. Rep."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100588_bib0017","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.ju.0000079761.56154.e5","article-title":"Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer","volume":"170","author":"Gaston","year":"2003","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100588_bib0018","doi-asserted-by":"crossref","first-page":"214","DOI":"10.21037\/tau.2017.09.11","article-title":"Racial disparities and considerations for active surveillance of prostate cancer","volume":"7","author":"Jiang","year":"2018","journal-title":"Transl. An-drol Urol."},{"issue":"16","key":"10.1016\/j.ctarc.2022.100588_bib0019","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality \u2014 the future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100588_bib0020","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of in-cidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2022.100588_bib0021","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1002\/cncr.31026","article-title":"Prostate cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study","volume":"123","author":"Steele","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100588_bib0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2022.100588_bib0024","doi-asserted-by":"crossref","unstructured":"Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The epidemiology of prostate cancer. Cold Spring Harb. Perspect. Med. 2018;8(12). doi:10.1101\/cshperspect.a030361.","DOI":"10.1101\/cshperspect.a030361"},{"key":"10.1016\/j.ctarc.2022.100588_bib0025","doi-asserted-by":"crossref","unstructured":"Chornokur G., Dalton K., Borysova M.E., Kumar N.B. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. The Prostate. 2011;71(9):985\u2013997. doi:10.1002\/pros.21314.","DOI":"10.1002\/pros.21314"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100588_bib0026","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1186\/s12889-018-5696-y","article-title":"Social determinants of prostate cancer in the Caribbean: a systematic review and meta-analysis","volume":"18","author":"Brown","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ctarc.2022.100588_bib0027","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sandra","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100588_bib0028","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guide-lines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100588_bib0029","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.eururo.2015.04.008","article-title":"Genomic predictors of outcome in prostate cancer","volume":"68","author":"Bostr\u00f6m","year":"2015","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100588_bib0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","article-title":"Germline and somatic mutations in prostate cancer for the clinician","volume":"17","author":"Cheng","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100588_bib0031","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ctarc.2022.100588_bib0032","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/cncr.31316","article-title":"Genetic testing for hereditary prostate cancer: current status and limitations","volume":"124","author":"Zhen","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100588_bib0033","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","article-title":"Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium","volume":"17","author":"Paller","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7_suppl","key":"10.1016\/j.ctarc.2022.100588_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.234","article-title":"PROPEL: a randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Clarke","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100588_bib0035","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.6004\/jnccn.2019.0044","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: colorectal, version 2.2019","volume":"17","author":"Gupta","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100588_bib0036","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100588_bib0037","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11912-020-0863-6","article-title":"Genetic testing in prostate cancer","volume":"22","author":"Sokolova","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100588_bib0038","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017","volume":"36","author":"Giri","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100588_bib0039","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.c.31602","article-title":"The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine","volume":"178","author":"Stoll","year":"2018","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:38:04Z","timestamp":1762843084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"alternative-id":["S2468294222000788"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100588","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100588"}}